- Home
- QNTM vs NRXP Comparison
QNTM vs NRXP Comparison
Compare QNTM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNTM
- NRXP
- Stock Information
- Founded
- QNTM 1998
- NRXP 2015
- Country
- QNTM Canada
- NRXP United States
- Employees
- QNTM N/A
- NRXP N/A
- Industry
- QNTM
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- QNTM
- NRXP Health Care
- Exchange
- QNTM NYSE
- NRXP Nasdaq
- Market Cap
- QNTM 35.6M
- NRXP 32.6M
- IPO Year
- QNTM N/A
- NRXP N/A
- Fundamental
- Price
- QNTM $20.76
- NRXP $3.51
- Analyst Decision
- QNTM
- NRXP Strong Buy
- Analyst Count
- QNTM 0
- NRXP 4
- Target Price
- QNTM N/A
- NRXP $28.50
- AVG Volume (30 Days)
- QNTM 414.2K
- NRXP 290.6K
- Earning Date
- QNTM 08-13-2025
- NRXP 08-13-2025
- Dividend Yield
- QNTM N/A
- NRXP N/A
- EPS Growth
- QNTM N/A
- NRXP N/A
- EPS
- QNTM N/A
- NRXP N/A
- Revenue
- QNTM N/A
- NRXP N/A
- Revenue This Year
- QNTM N/A
- NRXP N/A
- Revenue Next Year
- QNTM N/A
- NRXP N/A
- P/E Ratio
- QNTM N/A
- NRXP N/A
- Revenue Growth
- QNTM N/A
- NRXP N/A
- 52 Week Low
- QNTM $2.70
- NRXP $1.10
- 52 Week High
- QNTM $38.25
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- QNTM 54.17
- NRXP 60.51
- Support Level
- QNTM $20.89
- NRXP $2.90
- Resistance Level
- QNTM $38.25
- NRXP $3.61
- Average True Range (ATR)
- QNTM 4.22
- NRXP 0.27
- MACD
- QNTM 0.15
- NRXP -0.05
- Stochastic Oscillator
- QNTM 34.92
- NRXP 41.44
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.